Gilead Sciences, Inc. (NASDAQ:GILD) - Research analysts at Cantor Fitzgerald issued their FY2022 earnings per share estimates for Gilead Sciences in a report released on Wednesday, May 5th. Cantor Fitzgerald analyst A. Young expects that the biopharmaceutical company will post earnings of $6.29 per share for the year. Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 29th. The biopharmaceutical company reported $2.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.06 by $0.02. Gilead Sciences had a return on equity of 37.77% and a net margin of 5.48%.
A number of other research analysts have also issued reports on the company. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research report on Friday, April 30th. Sanford C. Bernstein upgraded Gilead Sciences from a "market perform" rating to an "outperform" rating and set a $80.00 target price on the stock in a research note on Thursday, April 1st. Morgan Stanley increased their target price on Gilead Sciences from $81.00 to $83.00 and gave the company an "overweight" rating in a research note on Monday. Credit Suisse Group upped their price target on Gilead Sciences from $65.00 to $66.00 and gave the company a "neutral" rating in a report on Friday, February 5th. Finally, SVB Leerink raised their price target on Gilead Sciences from $72.00 to $74.00 and gave the company an "outperform" rating in a report on Thursday. Ten equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock has an average rating of "Buy" and a consensus price target of $98.38.
GILD stock traded down $1.07 during midday trading on Thursday, hitting $65.44. 212,571 shares of the company's stock were exchanged, compared to its average volume of 8,328,119. Gilead Sciences has a 12-month low of $56.56 and a 12-month high of $80.92. The company has a current ratio of 3.25, a quick ratio of 3.15 and a debt-to-equity ratio of 1.65. The stock has a market capitalization of $82.39 billion, a price-to-earnings ratio of 68.57, a price-to-earnings-growth ratio of 0.67 and a beta of 0.51. The firm has a 50 day moving average price of $65.27 and a 200-day moving average price of $62.78.
Several hedge funds have recently added to or reduced their stakes in GILD. Norges Bank purchased a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $767,548,000. Dodge & Cox increased its stake in Gilead Sciences by 35.7% in the fourth quarter. Dodge & Cox now owns 17,107,888 shares of the biopharmaceutical company's stock valued at $996,706,000 after purchasing an additional 4,500,035 shares during the last quarter. Amundi Pioneer Asset Management Inc. increased its stake in Gilead Sciences by 43.2% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 6,157,567 shares of the biopharmaceutical company's stock valued at $358,717,000 after purchasing an additional 1,858,416 shares during the last quarter. Cibc World Markets Corp increased its stake in Gilead Sciences by 405.3% in the fourth quarter. Cibc World Markets Corp now owns 1,772,241 shares of the biopharmaceutical company's stock valued at $103,251,000 after purchasing an additional 1,421,508 shares during the last quarter. Finally, Morgan Stanley increased its stake in Gilead Sciences by 18.4% in the fourth quarter. Morgan Stanley now owns 7,124,342 shares of the biopharmaceutical company's stock valued at $415,063,000 after purchasing an additional 1,106,826 shares during the last quarter. Hedge funds and other institutional investors own 76.36% of the company's stock.
In other Gilead Sciences news, EVP Brett A. Pletcher sold 1,975 shares of the business's stock in a transaction dated Wednesday, February 10th. The shares were sold at an average price of $67.41, for a total transaction of $133,134.75. Following the sale, the executive vice president now directly owns 28,832 shares in the company, valued at $1,943,565.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard James Whitley sold 20,282 shares of the business's stock in a transaction dated Monday, May 3rd. The stock was sold at an average price of $64.57, for a total transaction of $1,309,608.74. Following the sale, the director now owns 51,404 shares in the company, valued at $3,319,156.28. The disclosure for this sale can be found here. Insiders sold 23,743 shares of company stock worth $1,536,896 in the last ninety days. 0.13% of the stock is currently owned by corporate insiders.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 29th. Shareholders of record on Tuesday, June 15th will be given a $0.71 dividend. The ex-dividend date is Monday, June 14th. This represents a $2.84 dividend on an annualized basis and a yield of 4.34%. Gilead Sciences's payout ratio is currently 46.25%.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
See Also: What is a stock portfolio tracker?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: The four types of profit margin7 Lithium Stocks That Will Power the Electric Vehicle Boom
Demand for lithium is set to increase exponentially in the next few years. In fact, according to Statista, demand for lithium may very well double to 820,000 tons in that time. Some of that demand will come from companies that are manufacturing the batteries that we use every day. For example, lithium is an essential component of the batteries that power our mobile devices.
But the real growth will come as the United States goes all-in on electric vehicles (EVs). The Biden administration recently announced plans to have the U.S. government’s fleet of over 600,000 vehicles converted to EVs.
And as you’re aware, EV stocks are in a bubble of some sort at the moment. Some of that is due to the increasing number of companies that went public last year. However, as investors are beginning to realize, not all of these companies will be the next Tesla. In fact, some of these companies may never be successful at bringing an EV to market, at least not at the scale that will be required.
The ones that do make it will need lithium and lots of it. To help you sift through the best lithium stocks to buy, we’ve put together this special presentation.
View the "7 Lithium Stocks That Will Power the Electric Vehicle Boom"